Results 61 to 70 of about 303,632 (262)
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Background The prevalence of iron deficiency with anemia and iron deficiency without anemia (IDWA) during pregnancy have not been summarized, and evidence of the direct association of IDWA with adverse perinatal outcomes (APO) are unknown.
Lucky O. Lawani +6 more
wiley +1 more source
Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
Case Reports in Oncology, 2020 Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation.
Ahmed M. Abdalhadi, Mohamed A. Yassin
doaj +1 more source
Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]
, 2017 We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene +5 more
core +1 more source
Thromboembolic events in polycythemia vera
Annals of Hematology, 2019 Thromboembolic events and cardiovascular disease are the most prevalent complications in patients with polycythemia vera (PV) compared with other myeloproliferative disorders and are the major cause of morbidity and mortality in this population. Moreover,
M. Griesshammer, J. Kiladjian, C. Besses
semanticscholar +1 more source
The role of a low erythropoietin level for the polycythemia vera diagnosis.
Blood Cells, Molecules & Diseases, 2020 A low erythropoietin (EPO) level is a minor diagnostic criterion for polycythemia vera (PV). Controversies exist regarding the diagnostic value of a low EPO level when considering increasing availability of advanced molecular testing.
Oleksandra Lupak +5 more
semanticscholar +1 more source
Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
JEADV Clinical Practice, EarlyView.ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson +4 more
wiley +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
Movement Disorders Clinical Practice, EarlyView.ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan +4 more
wiley +1 more source
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
Haematologica, 2017 Polycythemia vera is a clonal disorder of hematopoietic stem/progenitor cells. It manifests as an expansion of red cell mass. It is the most common chronic myeloproliferative neoplasm. In virtually all cases, it is characterized by a V617F point mutation
Alessandro M. Vannucchi
doaj +1 more source
Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]
, 2016 Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita +2 more
core +1 more source